New Clinical Trials on Insulin Glargine gives New Hope for those with Type-2 Diabetes
Insulin Glargine gives New Hope for those with Type-2 Diabetes in New Clinical Trials
Anti-Diabetic, Drug Research & Development API, Patent Expiration 2023 Tags: anti-diabetic Dec 31, 2015
New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2023 Tags: AIDSHIV Dec 21, 2015
Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1. The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property[…]
Saxagliptin Hydrochloride- The Most Efficient Substitute for Insulin
Anti-Diabetic, Drug Research & Development API, Gliptin, Patent Expiration 2023 Tags: Saxagliptin Dec 15, 2015
The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes. The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was[…]
